Insights

Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?

This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?
The post Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? appeared first on The Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Hand with blue medical gloves holds vials of coronavirus vaccines

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

All eyes were on the biotech Moderna (NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year, while the S&P 500 has gained 16%.

On Dec. 11, Pfizer (NYSE: PFE) and its German biotech partner BioNTech (NASDAQ: BNTX) became the first to receive an Emergency Use Authorization (EUA) from the Food and Drug Administration for a coronavirus vaccine candidate, BNT162b2. Moderna became the second company to receive the EUA for its vaccine, mRNA-1273, on Dec. 18. The former vaccine displayed 95% efficacy while the latter showed 94.1% efficacy in the still-ongoing phase 3 trials.

So now that Moderna’s vaccine is out and the inoculation process has begun, is the company still a good investment?

Now that the vaccines are out, we will see how effective they are in treating COVID-19. At one point in December, Moderna’s stock had surged up to 768%, but it seems to be simmering down now. That could be because the vaccine market has tremendous competition, and ultimately the value of one particular vaccine might decline. 

Investing in this market is risky. Moderna did wonders in a short period, but its future heavily depends on its COVID-19 vaccine. Most of its other vaccines in clinical trials use the same mRNA technology, so the success of mRNA-1273 will validate other treatments in its pipeline. There’s a lot riding on the vaccine’s success.

MRNA Chart

MRNA data by YCharts.

If you’re already invested in Moderna, I would suggest holding it. And any investors who still want an entry in this risky game should keep their allocation small with this biotech.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!